Taronis Technologies (formerly MagneGas) has announced its preliminary sales figures for January. These show the seven successive acquisitions made over the last year driving a fivefold year-on-year increase in monthly sales to $1.42m. Importantly, the figures show 42% growth compared with December, as activity has picked up after the holiday period.
Written by
Taronis Technologies |
Good start to FY19 sales |
Alternative energy |
15 February 2019 |
Share price performance
Business description
Analyst
Taronis Technologies is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||
Taronis Technologies (formerly MagneGas) has announced its preliminary sales figures for January. These show the seven successive acquisitions made over the last year driving a fivefold year-on-year increase in monthly sales to $1.42m. Importantly, the figures show 42% growth compared with December, as activity has picked up after the holiday period.
Year end |
Revenue (US$m) |
EBITDA |
PBT* |
EPS* |
DPS |
P/E |
12/16 |
3.6 |
(9.6) |
(10.3) |
(620.5)** |
0.0 |
N/A |
12/17 |
3.7 |
(10.3) |
(11.0) |
(306.2)** |
0.0 |
N/A |
12/18e |
10.0 |
(11.5) |
(13.7) |
(4.29)** |
0.0 |
N/A |
12/19e |
18.8 |
(5.6) |
(7.3) |
(0.36)** |
0.0 |
N/A |
Note: Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **Adjusted for reverse share splits.
Taronis completed its most recent acquisition, which was of one of the largest remaining independent industrial gas and welding supply distributors in East Texas, partway through January. Had this business been part of the group at the beginning of the month, sales would have risen by 600% year-on-year to $1.75m. This gives potential for upgrades to our estimates and could take the group close to reaching the $20–23m annual sales that management estimates is required for Taronis to be profitable and generate cash for re-investing in its water decontamination technology.
Looking at organic growth, the Californian operations generated their second highest monthly sales as they benefited from demand for industrial gases used in commercial production of cannabis. Sales in Florida grew by 17% year-on-year. Sales at Green Arc, with locations in Texas and Louisiana, grew by 48% sequentially. While some of this growth reflects a recovery after the holiday period, management notes that new client acquisitions made in late 2018 have begun to ramp up.
Earlier this month, Taronis announced a placing of 10.8m new shares at $1.25/share together with warrants to purchase up to 8.1m new shares, also exercisable at $1.25/share. This is expected to raise $13.5m (gross). Although this has had a highly dilutive impact, with FY19 EPS falling from $0.79/share to $0.36/share (we do not make any other changes to our estimates), management notes that the group is now well funded for the foreseeable future.
|
Disclaimer
|
|
Disclaimer
|
Research: Investment Companies
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital, one of the leading global healthcare asset managers. The year 2018 proved to be tough for the trust’s performance as biotech companies delivering negative news were heavily penalised, while those delivering good news went unrewarded. However, the managers are optimistic about BIOG’s prospects. They cite a rich industry innovation pipeline that includes a series of technologies with multi-billion-dollar revenue potential; a favourable regulatory environment; and a higher level of deal activity, including major pharma company Bristol-Myers Squibb’s recent bid for Celgene (one of BIOG’s largest holdings) at a significant premium to its pre-bid share price.